Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women

Journal of Bone and Mineral Research

Volumn 23, Issue 7, 2008, Pages 1106-1117

  Bhattacharyya, Sudeepa ^a   Siegel, Eric R ^a   Achenbach, Sara J ^b   Khosla, Sundeep ^b   Suva, Larry J ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Biomarkers; Bone turnover; Fracture risk; Surface enhanced laser desorption ionization time of flight mass spectrometry

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN; GLYCOPROTEIN; INTERALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4 PRECURSOR; KALLIKREIN; PROTEOME;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; DIAGNOSTIC VALUE; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FEMALE; FRACTURE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MEASUREMENT; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; FEMALE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 45849153982     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080235     Document Type: Article

References (41)

1. U.S. Surgeon General 2004 Surgeon General Report: Bone Health and Osteoporosis. International Medical Publishing, McLean, VA, USA.
2. National Institutes of Health 2001 Osteoporosis prevention, diagnosis and therapy. JAMA 285:785-795.
3. Kanis JA, Glüer CC 2001 An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192-202.
4. McGarry KA, Kiel DP 2000 Postmenopausal osteoporosis: Strategies for preventing bone loss, avoiding fracture. Postgrad Med 108:79-91.
5. Kanis JA 2000 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936.
6. Garnero P, Delmas PD 2004 Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskel Neuron Interact 4:50-63.
7. Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026.
8. Dogan E, Posaci C 2002 Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women. Postgrad Med J 78:727-731.
9. Garnero P, Delmas PD 2004 Contribution of bone mineral density and bone turnover markers to the estimation of riskof osteoporotic fracture in postmenopausal women. J Musculoskel Neuron Interact 4:50-63.
10. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526-1536.
11. Merchant M, Weinberger SR 2000 Recent advancements in surface enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21:1164-1167.
12. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS 2004 Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6:674-686.
13. Bhattacharyya S, Epstein J, Suva LJ 2005 Biomarkers that discriminate Multiple Myeloma Patients With or Without Skeletal Involvement Detected Using SELDI-TOF Mass Spectrometry and Statistical and Machine Learning Tools. Dis Markers 22:245-255.
14. Marguiles AG, Klimberg VS, Bhattacharyya S, Gaddy D, Suva LJ 2006 Genomics and proteomics of bone cancer. Clin Cancer Res 12:6217s-6221s.
15. Kohli M, Siegel ER, Bhattacharyya S, Khan MA, Shah R, Suva LJ 2006 Surface enhanced laser desorption/ionization time of flight-mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomarkers 2:249-258.
16. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharyya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ 2005 Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res 65:11001-11009.
17. Liotta LA, Petricoin EF 2006 Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30.
18. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA 2002 Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577.
19. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R 2003 Identification of biomarkers for ovarian cancer using strong anion-exchange Protein-Chips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100:12343-12348.
20. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr 2002 Boosted decision tree analysis of surface-enhanced laser desorption/ ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48:1835-1843.
21. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M 2004 Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860-868.
22. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF III 2001 Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17:301-307.
23. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW 2002 Proteomics and Bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304.
24. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJO, Johnson PJ, Martin A 2006 Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94:1898-1905.
25. Perrien DS, Achenbach SJ, Bledsoe SE, Walser B, Suva LJ, Khosla S, Gaddy D 2006 Bone turnover across the menopause transition: Correlations with inhibins and FSH. J Clin Endocrinol Metab 91:1848-1854.
26. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274.
27. Melton LJ III 1996 History of the Rochester Epidemiology Project. Mayo Clin Proc 71:266-274.
28. Collom SL, Jamakhandi AP, Tackett AJ, Radominska-Pandya A, Miller GP 2007 CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys 459:59-69.
29. Breiman L, Friedman JH, Olshen RA, Stone CJ 1984 Classification and Regression Trees. Wadsworth International Group, Belmont, CA, USA.
30. Breiman L 1996 Bagging predictors. Mach Learn 24:123-140.
31. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL, McGuire M, Podust VN, Li G, Chatterjee N, Mu R, Yin S, Rothman N, Smith MT 2005 Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci USA 102:17041-17046.
32. Suriano R, Lin Y, Ashok BT, Schaefer SD, Schantz SP, Geliebter J, Tiwari RK 2006 Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J Proteome Res 5:856-861.
33. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR 2005 Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115:783-789.
34. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, Choi-Miura NH, Goggins M, Chan DW, Zhang Z 2006 Quantification of fragments of human serum Inter-alpha-trypsin Inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization based immunoassay. Clin Chem 52:1045-1053.
35. Diamandis EP 2004 Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics 3:367-378.
36. Diamandis EP 2004 Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst 96:353-356.
37. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P 2006 Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284.
38. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R 2005 Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11:1110-1118.
39. Zhang Z 2004 Three biomarkers identified from serum proteomic changes for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890.
40. Whicher J, Biasucci L, Rifai N 1999 Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 37:495-503.
41. Romette J, di Costanzo-Dufetel J, Charrel M 1986 Inflammatory syndrome and changes in plasma proteins. Pathol Biol (Paris) 34:1006-1012.